MAP2K7 and melanoma: Treatment of BRAF-V600E-expressing melanomas with combined BRAF/MEK inhibitor therapy (dabrafenib plus trametinib) has resulted in a 5-year survival rate of 34% in BRAF mutant metastatic melanoma [10].